![conference banner](/images/conference-banner.jpeg)
Abstract
Type 2 diabetes (T2D) is a metabolic disorder characterised by the inability of β-cells to secrete enough insulin to maintain glucose homeostasis. Pancreatic β-cells secrete insulin in a biphasic manner, first and second phase insulin secretion, and loss of first phase insulin secretion is an independent predictor of T2D onset. Restoration of first phase insulin secretion has been shown to improve blood glucose in T2D by suppressing hepatic glucose production and priming insulin sensitive tissue to more readily take up glucose and has thus prompted numerous studies into its regulation. First phase insulin secretion is initiated primarily by the classical triggering pathway, a complex system comprised of multiple stimulatory signals. Recent studies have identified a number of novel regulatory factors that are crucial for first phase insulin secretion and glucose homeostasis. These include, among others, hypoxia inducible factor 1α, von Hippel-Lindau, factor inhibiting HIF, nicotinamide phospho-ribosyl-transferase, and the sirtuin family. This review will outline how first phase insulin secretion is initiated and detail some of the recent findings in its regulation.
Keywords: Aryl hydrocarbon nuclear translocator, glucose homeostasis, hypoxia inducible factor-1α, insulin secretion, regulatory genes, type 2 diabetes
Current Molecular Medicine
Title:First Phase Insulin Secretion and Type 2 Diabetes
Volume: 13 Issue: 1
Author(s): K. Cheng, S. Andrikopoulos and J. E. Gunton
Affiliation:
Keywords: Aryl hydrocarbon nuclear translocator, glucose homeostasis, hypoxia inducible factor-1α, insulin secretion, regulatory genes, type 2 diabetes
Abstract: Type 2 diabetes (T2D) is a metabolic disorder characterised by the inability of β-cells to secrete enough insulin to maintain glucose homeostasis. Pancreatic β-cells secrete insulin in a biphasic manner, first and second phase insulin secretion, and loss of first phase insulin secretion is an independent predictor of T2D onset. Restoration of first phase insulin secretion has been shown to improve blood glucose in T2D by suppressing hepatic glucose production and priming insulin sensitive tissue to more readily take up glucose and has thus prompted numerous studies into its regulation. First phase insulin secretion is initiated primarily by the classical triggering pathway, a complex system comprised of multiple stimulatory signals. Recent studies have identified a number of novel regulatory factors that are crucial for first phase insulin secretion and glucose homeostasis. These include, among others, hypoxia inducible factor 1α, von Hippel-Lindau, factor inhibiting HIF, nicotinamide phospho-ribosyl-transferase, and the sirtuin family. This review will outline how first phase insulin secretion is initiated and detail some of the recent findings in its regulation.
Export Options
About this article
Cite this article as:
Cheng K., Andrikopoulos S. and E. Gunton J., First Phase Insulin Secretion and Type 2 Diabetes, Current Molecular Medicine 2013; 13 (1) . https://dx.doi.org/10.2174/1566524011307010126
DOI https://dx.doi.org/10.2174/1566524011307010126 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Correlated Factors of Serum CA19-9 Levels in Diabetic Patients
Current Diabetes Reviews Glucose Blood Levels as a Therapeutic Target in Acute Ischaemic Stroke Setting
Current Topics in Medicinal Chemistry New Antipsychotics and Schizophrenia: A Review on Efficacy and Side Effects
Current Medicinal Chemistry Estrogen and Serotonin: Complexity of Interactions and Implications for Epileptic Seizures and Epileptogenesis
Current Neuropharmacology Continuous Subcutaneous Insulin Infusion (CSII) in Diabetic Pregnancy: A Review
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Type 1 Diabetes Mellitus Clinical Profile and Follow-up: North Emirate Hospitals’ Experience
New Emirates Medical Journal Erythropoietin and Oxidative Stress
Current Neurovascular Research Stem Cell-Based Immunomodulation in Type 1 Diabetes: Beyond the Regenerative Approach
Current Pharmaceutical Design Editorial [Hot Topic:Continuous Glucose Monitoring Systems: Toys or Tools (Guest Editor: Christophe De Block)]
Current Diabetes Reviews Maturity-Onset Diabetes of the Young: An Overview with Focus on the Middle East
Current Molecular Medicine EDITORIAL (Thematic Issue: Retinal Neurodegeneration in the Course of Diabetes: Neuroprotection as a Potential Treatment Target)
Current Neuropharmacology Characteristics and Outcomes of Children with Type-I Diabetes Mellitus Hospitalized for Ketoacidosis
Current Diabetes Reviews Blood-Brain Barrier Integrity and Glial Support: Mechanisms that can be Targeted for Novel Therapeutic Approaches in Stroke
Current Pharmaceutical Design Glycaemic Control in Cardiac Surgery Patients: a Double-Edged Sword
Current Vascular Pharmacology Neural Stem Cell Niches in Health and Diseases
Current Pharmaceutical Design Hyperglycemic Hyperosmolar State Associated with Low-Dose Quetiapine Treatment in a Patient with Bipolar Disorder
Current Drug Safety Transition of Care for Patients with Diabetes
Current Diabetes Reviews Mechanisms of Hormonal Regulation of Sertoli Cell Development and Proliferation: A Key Process for Spermatogenesis
Current Molecular Pharmacology Methemoglobinaemia in Diabetic Ketoacidosis Patient
New Emirates Medical Journal Women and Schizophrenia: Sex-Based Pharmacotherapy
Current Psychiatry Reviews